We are live on ! Find out more
AERI

Aerie Pharmaceuticals
AERI

Delisted

AERI was delisted on the 18th of November, 2022.

Back to rankings

182 hedge funds and large institutions have $1.83B invested in Aerie Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 78 increasing their positions, 47 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

88% more call options, than puts

Call options by funds: $33.7M | Put options by funds: $18M

66% more repeat investments, than reductions

Existing positions increased: 78 | Existing positions reduced: 47

58% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 19

6% more funds holding

Funds holding: 172 → 182 (+10)

1% more capital invested

Capital invested by funds: $1.81B → $1.83B (+$16.8M)

22% less funds holding in top 10

Funds holding in top 10: 9 → 7 (-2)

Holders
182
Holders Change
+10
Holders Change %
+5.81%
% of All Funds
4.54%
Holding in Top 10
7
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-22.22%
% of All Funds
0.17%
New
30
Increased
78
Reduced
47
Closed
19
Calls
$33.7M
Puts
$18M
Net Calls
+$15.8M
Net Calls Change
+$17.9M

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$84.7M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$46M
3
PHS
PFM Health Sciences
California
+$36.3M
4
Loomis, Sayles & Company
Loomis, Sayles & Company
Massachusetts
+$15.2M
5
WRF
Waddell & Reed Financial
Kansas
+$14.8M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$21.5M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$20.5M
3
DM
Deerfield Management
New York
-$17.9M
4
Deutsche Bank
Deutsche Bank
Germany
-$17.6M
5
BC
Broadfin Capital
New York
-$13.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
Loomis, Sayles & Company
26
Loomis, Sayles & Company
Massachusetts
$13.5M +$15.2M +278,209 New
T. Rowe Price Associates
27
T. Rowe Price Associates
Maryland
$13.3M +$2.29M +41,971 +18%
Millennium Management
28
Millennium Management
New York
$12.9M -$11.4M -208,658 -44%
Norges Bank
29
Norges Bank
Norway
$12.5M +$14.1M +257,834 New
RHJA
30
Rice Hall James & Associates
California
$11.4M -$522K -9,561 -4%
SAM
31
Senzar Asset Management
New York
$11.2M -$8.74M -160,200 -41%
Axa
32
Axa
France
$10M -$156K -2,863 -1%
Fidelity Investments
33
Fidelity Investments
Massachusetts
$9.99M -$5.42M -99,393 -33%
Citadel Advisors
34
Citadel Advisors
Florida
$9.93M +$5.97M +109,462 +115%
Alyeska Investment Group
35
Alyeska Investment Group
Illinois
$9.3M +$7.16M +131,282 +219%
TA
36
Teachers Advisors
New York
$8.51M +$82.4K +1,510 +0.9%
AL
37
Appaloosa LP
New Jersey
$8.25M -$1.09M -20,000 -11%
O
38
OppenheimerFunds
New York
$8.24M +$9.25M +169,490 New
Goldman Sachs
39
Goldman Sachs
New York
$8.13M -$2.05M -37,600 -18%
Charles Schwab
40
Charles Schwab
California
$7.42M +$785K +14,379 +10%
CM
41
Castleark Management
Illinois
$6.42M +$2.98M +54,580 +70%
Handelsbanken Fonder
42
Handelsbanken Fonder
Sweden
$6.32M – – –
RPAM
43
Rhenman & Partners Asset Management
Sweden
$5.88M +$2.51M +45,932 +61%
CS
44
Credit Suisse
Switzerland
$5.68M +$3.31M +60,678 +108%
DCM
45
DAFNA Capital Management
California
$5.67M +$546K +10,000 +9%
TAM
46
Tocqueville Asset Management
New York
$5.27M -$1.04M -19,000 -15%
NCGI
47
Next Century Growth Investors
Minnesota
$4.9M -$2.03M -37,197 -27%
TCIM
48
TIAA CREF Investment Management
New York
$4.88M -$1.3M -23,841 -19%
Morgan Stanley
49
Morgan Stanley
New York
$4.86M -$2.11M -38,668 -28%
IHM
50
Iguana Healthcare Management
New York
$4.86M +$273K +5,000 +5%
1
2
3 4 5

AERI Hedge Fund Activity: Q3 2017 in Review

182 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q3 2017, worth a combined $1.83B — up 0.93% from $1.81B a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new AERI positions and 19 closed out — a net gain of 11 holders — while 78 added to existing stakes and 47 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $84.7M. The largest seller was OrbiMed, cutting an estimated $21.5M.

  • 182 institutional investors held Aerie Pharmaceuticals (AERI) as of Q3 2017, up from 172 in Q2 2017.
  • Funds reported $1.83B of Aerie Pharmaceuticals stock for Q3 2017, up 0.93% quarter-over-quarter.
  • 30 funds opened new Aerie Pharmaceuticals positions in Q3 2017 and 19 closed out, a net change of +11 holders.
  • The largest Aerie Pharmaceuticals buyer in Q3 2017 was Wellington Management Group, an estimated $84.7M added.
  • The largest Aerie Pharmaceuticals seller in Q3 2017 was OrbiMed, an estimated $21.5M sold.

Based on aggregated 13F filings for Q3 2017.